InsidersTradesSigma
Total declarations
Companies
▲ Purchases (68 ops.)
▼ Sales (19 ops.)
Insider track record
CEODisclosed buys
68
Disclosed sells
19
T+90 hit rate
58%
T+90 mean return
+1.7%
Across 19 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by BVF PARTNERS L P/IL, Managing Director. Officer active across 21 companies, notably Rain Therapeutics Inc.. Cumulatively, 103 filings have been published. Breakdown: 68 buys · 19 sells. Total volume traded: €472.2m. History available since 13 May 2021. The latest transaction was filed on 30 June 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations103 total
837,914 sharesCommon Stock, $0.0001 par valueSEC:0000921895-26-001688:0
627,597 sharesCommon Stock, $0.0001 par valueSEC:0000921895-26-001688:1
113,289 sharesCommon Stock, $0.0001 par valueSEC:0000921895-26-001688:2
51,858 sharesCommon Stock, $0.0001 par valueSEC:0000921895-26-001688:3
6,194,145 sharesCommon StockSEC:0000921895-25-002742:0
4,726,743 sharesCommon StockSEC:0000921895-25-002742:1
560,797 sharesCommon StockSEC:0000921895-25-002742:2
142,604 shares@ US$44.0010.8% of flowCommon Stock, $0.0001 par valueSEC:0000921895-25-001910:0
Ideal exit: 27 Mar 2026 (T+270)
115,783 shares@ US$44.008.7% of flowCommon Stock, $0.0001 par valueSEC:0000921895-25-001910:1
Ideal exit: 27 Mar 2026 (T+270)
58,780 shares@ US$44.004.4% of flowCommon Stock, $0.0001 par valueSEC:0000921895-25-001910:2
Ideal exit: 27 Mar 2026 (T+270)
127,407 shares@ US$27.1015.9% of flowCommon Stock, $0.0075 par value per shareSEC:0000921895-25-001602:0
8,679,726 sharesCommon Stock, $0.001 par valueSEC:0000921895-25-001590:0
339,679 shares@ US$26.1043.9% of flowCommon Stock, $0.0075 par value per shareSEC:0000921895-25-000177:0
85,776 shares@ US$26.1011.1% of flowCommon Stock, $0.0075 par value per shareSEC:0000921895-25-000177:1
75,287 shares@ US$26.109.7% of flowCommon Stock, $0.0075 par value per shareSEC:0000921895-25-000177:2
149,975 shares@ US$26.1019.4% of flowCommon Stock, $0.0075 par value per shareSEC:0000921895-25-000177:3
235,450 sharesCommon stock, $0.0001 par valueSEC:0000921895-25-000106:0
161,810 sharesCommon stock, $0.0001 par valueSEC:0000921895-25-000106:1
22,740 sharesCommon stock, $0.0001 par valueSEC:0000921895-25-000106:2
234,323 sharesCommon Stock, $0.001 par valueSEC:0000921895-24-002972:0
1,797,527 sharesCommon stock, $0.0001 par valueSEC:0000921895-24-002886:0
3,062,000 sharesCommon Stock, $0.0001 par valueSEC:0000921895-24-002631:0
538,420 shares@ US$14.3094.0% of flowCommon StockSEC:0000921895-24-002409:0
1,030,589 shares@ US$50.001651.5% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-24-002263:0
836,862 shares@ US$50.001641.8% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-24-002263:1
25 of 103 declarations
About BVF PARTNERS L P/IL
Public sources indicate that Gorjan Hrustanovic is a Managing Director at BVF Partners L.P., focused on biotechnology and therapeutic investments, and that he has held that role since September 2015. SEC filings and proxy materials for Kymera Therapeutics and Olema Pharmaceuticals also say he serves on the boards of Kymera Therapeutics and Olema Pharmaceuticals. Those same public sources connect him to the listed companies through BVF Partners L.P., but they do not provide a more detailed biography within the requested scope. Sources: https://www.sec.gov/Archives/edgar/data/1724979/000119312521105078/d26404ds1.htm
